(Q46076222)

19 December 2017

title

Risk of severe gastrointestinal events in women treated with monthly ibandronate or weekly alendronate and risedronate (English)

1 reference

19 December 2017

author name string

William A Blumentals

1

1 reference

19 December 2017

Steven T Harris

2

1 reference

19 December 2017

Raymond E Cole

3

1 reference

19 December 2017

Liping Huang

4

1 reference

19 December 2017

Stuart L Silverman

5

1 reference

19 December 2017

language of work or name

English

0 references

publication date

24 March 2009

1 reference

19 December 2017

Annals of Pharmacotherapy

published in

1 reference

19 December 2017

volume

43

1 reference

19 December 2017

issue

4

1 reference

19 December 2017

page(s)

577-585

1 reference

19 December 2017

Upper gastrointestinal and overall tolerability of alendronate once weekly in patients with osteoporosis: results of a randomized, double-blind, placebo-controlled study

cites work

1 reference

Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group.

21 January 2018

1 reference

Upper gastrointestinal tract safety of risedronate: a pooled analysis of 9 clinical trials

21 January 2018

1 reference

Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases

21 January 2018

1 reference

Tolerability and compliance with risedronate in clinical practice

21 January 2018

1 reference

Early discontinuation of treatment for osteoporosis

21 January 2018

1 reference

Gastrointestinal adverse effects of bisphosphonates: etiology, incidence and prevention

21 January 2018

1 reference

Oral bisphosphonates and upper gastrointestinal tract problems: what is the evidence?

21 January 2018

1 reference

Adherence to and gastrointestinal tolerability of monthly oral or quarterly intravenous ibandronate therapy in women with previous intolerance to oral bisphosphonates: a 12-month, open-label, prospective evaluation

21 January 2018

1 reference

Patient preference for once-monthly ibandronate versus once-weekly alendronate in a randomized, open-label, cross-over trial: the Boniva Alendronate Trial in Osteoporosis (BALTO).

21 January 2018

1 reference

What the gastroenterologist should know about the gastrointestinal safety profiles of bisphosphonates

21 January 2018

1 reference

Results of multivariable logistic regression, propensity matching, propensity adjustment, and propensity-based weighting under conditions of nonuniform effect.

21 January 2018

1 reference

Treatment with once-weekly alendronate 70 mg compared with once-weekly risedronate 35 mg in women with postmenopausal osteoporosis: a randomized double-blind study

21 January 2018

1 reference

Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group

21 January 2018

1 reference

Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial

21 January 2018

1 reference

Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group

21 January 2018

1 reference

Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group.

21 January 2018

1 reference

Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group

21 January 2018

1 reference

Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis.

21 January 2018

1 reference

Ibandronate produces significant, similar antifracture efficacy in North American and European women: new clinical findings from BONE.

21 January 2018

1 reference

The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis

21 January 2018

1 reference

Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study

21 January 2018

1 reference

Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study

21 January 2018

1 reference

Ibandronate for the prevention of nonvertebral fractures: a pooled analysis of individual patient data

21 January 2018

1 reference

Ibandronate and the risk of non-vertebral and clinical fractures in women with postmenopausal osteoporosis: results of a meta-analysis of phase III studies

21 January 2018

1 reference

Efficacy and safety of risedronate 150 mg once a month in the treatment of postmenopausal osteoporosis

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1345/APH.1L555

1 reference

19 December 2017

1 reference

19 December 2017